References
- Weatherall D, Akinyanju O, Fucharoen S, Olivieri N, Musgrove PInherited disorders of hemoglobin. In:, Jamison D T, Breman J G, Measham A R, Alleyne G, Claeson M, Evans D B, et al.., editors. Disease control priorities in developing countries. 2nd ed. Washington (DC): World Bank; 2006. Chapter 34; p. 663–80.
- Cooley TB, Lee OP. Series of cases of splenomegaly in children with anemia and peculiar bone changes. Trans Amer Pediatr Soc. 1925;37:29.
- Rietti F. Ittero emolytica primitive. Atti Acad Scient Med Nat Ferrara. 1925;2:14–9.
- Valentine WN, Neel JV. Hematologic and genetic study of the transmission of thalassemia. Arch Int Med. 1944;74:185.
- Weatherall DJ, Clegg JB. Thalassemia — a global public health problem. Nat Med. 1996;2:847–9.
- Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86:480–7.
- Weatherall DJ. Genetic variation and susceptibility to infection: the red cell and malaria. Br J Haematol. 2008;141:276–86.
- Lo YM. Fetal nucleic acids in maternal blood: the promises. Clin Chem Lab Med. In press 2011.
- Higgs DR, Engel JD, Stamatoyannopoulos G. Thalassaemia. Lancet. In press 2011.
- Olivieri NF. The beta-thalassaemias. N Engl J Med. 1999;341:99–109.
- Nemeth E. Hepsidin in beta-thalassaemia. Ann N Y Acad Sci. 2010;1202:31–5.
- Porter JB, Shah FT. Iron overload in thalassemia and related conditions: Therapeutic goals and assessment of response to chelation therapies. Hematol Oncol Clin N Am. 2010;24:1109–30.
- Cao A, Galanello R. Beta-thalassemia. Genet Med. 2010;12:61–76.
- Cohen A, Gayer R, Mizanin J. Long term effect of splenectomy on transfusion requirements in thalassaemia major. Am J Hematol. 1989;30:254–6.
- Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, et al.. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171–9.
- Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood. 2000;95:1229–36.
- Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood. 2003;102:17–24.
- Aydinok Y, Ulger Z, Nart D, Terzi A, Cetiner N, Ellis G, et al.. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major. Haematologica. 2007;92:1599–606.
- Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, et al.. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107:3738– 44.
- Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, et al.. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115:1876–84.
- Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, et al.. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years’ follow-up. Blood. 2011;118:884–93.
- Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, et al.. Continued improvement and normalization of myocardial T2* in patients with beta-thalassemia major treated with Deferasirox (Exjade®) for up to 3 years. ASH 2010 Blood. 2010;116:abstract 4276.
- Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10:42.
- Angelucci E. Hematopoietic stem cell transplantation in thalassemia. 2010;2010:456–62.